BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14606097)

  • 1. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
    Bai YR; Wu GH; Guo WJ; Wu XD; Yao Y; Chen Y; Zhou RH; Lu DQ
    World J Gastroenterol; 2003 Nov; 9(11):2561-4. PubMed ID: 14606097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
    Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
    Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
    Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
    Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
    Goldstein D; Van Hazel G; Walpole E; Underhill C; Kotasek D; Michael M; Shapiro J; Davies T; Reece W; Harvey J; Spry N
    Br J Cancer; 2007 Aug; 97(4):464-71. PubMed ID: 17653074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
    Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
    Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
    Talamonti MS; Catalano PJ; Vaughn DJ; Whittington R; Beauchamp RD; Berlin J; Benson AB
    J Clin Oncol; 2000 Oct; 18(19):3384-9. PubMed ID: 11013279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
    Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G
    Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
    Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
    Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
    Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
    Haddock MG; Swaminathan R; Foster NR; Hauge MD; Martenson JA; Camoriano JK; Stella PJ; Tenglin RC; Schaefer PL; Moore DF; Alberts SR
    J Clin Oncol; 2007 Jun; 25(18):2567-72. PubMed ID: 17577035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
    Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
    Abelson JA; Murphy JD; Minn AY; Chung M; Fisher GA; Ford JM; Kunz P; Norton JA; Visser BC; Poultsides GA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e595-601. PubMed ID: 22197234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.